AKT1 and central nervous system cancer: We found amplification of EGFR (12.5% in low-grade and 31.8% in high-grade gliomas: 7.7% in GBM), PI3K (50% and 45% of low- and high-grade gliomas, respectively) and AKT (25% in low-grade and 13,6% in high-grade gliomas).